Evolving therapeutic paradigms for HIV and HCV
- 13 November 2003
- journal article
- review article
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 14 (6) , 634-640
- https://doi.org/10.1016/j.copbio.2003.10.012
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavirAntiviral Research, 2003
- Improving lopinavir genotype algorithm through phenotype correlationsAIDS, 2003
- Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2003
- Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside AnalogsJournal of Biological Chemistry, 2003
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyAIDS, 2003
- Antiretroviral Treatment for Adult HIV Infection in 2002JAMA, 2002
- Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DFAIDS, 2002
- Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced PatientsJournal of Virology, 2001
- Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trialAIDS, 1999
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance developmentMedicinal Research Reviews, 1996